The extracellular domain of myelin oligodendrocyte glycoprotein elicits atypical experimental autoimmune encephalomyelitis in rat and Macaque species

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Curtis, Alan D ^a   Taslim, Najla ^a   Reece, Shaun P ^a   Grebenciucova, Elena ^a,b   Ray, Richard H ^a   Rosenbaum, Matthew D ^a   Wardle, Robert L ^a   Van Scott, Michael R ^a   Mannie, Mark D ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; FREUND ADJUVANT; IMMUNOGLOBULIN G ANTIBODY; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; GAMMA INTERFERON; IMMUNOGLOBULIN G;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; BRAIN STEM; CONTROLLED STUDY; DEMYELINATION; DISEASE DURATION; DISEASE MODEL; EMBRYO; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; LIMB WEAKNESS; MYOTONIA; NONHUMAN; PARALYSIS; PROTEIN DOMAIN; RAT; SPINAL CORD; TORTICOLLIS; ANIMAL; IMMUNOLOGY; LEWIS RAT; MACACA FASCICULARIS; MALE;

RATTUS;

ANIMALS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; IMMUNOGLOBULIN G; INTERFERON-GAMMA; MACACA FASCICULARIS; MALE; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; RATS; RATS, INBRED LEW;

EID: 84907841700     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0110048     Document Type: Article

References (51)

1. Lassmann H (2013) Pathology and disease mechanisms in different stages of multiple sclerosis. J Neurol Sci 333: 1-4.
2. Geurts JJ, Barkhof F (2008) Grey matter pathology in multiple sclerosis. Lancet Neurol 7: 841-851.
3. Trapp BD, Nave KA (2008) Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci 31: 247-269.
4. Simmons SB, Pierson ER, Lee SY, Goverman JM (2013) Modeling the heterogeneity of multiple sclerosis in animals. Trends Immunol 34: 410-422.
5. Batoulis H, Recks MS, Addicks K, Kuerten S (2011) Experimental autoimmune encephalomyelitis-achievements and prospective advances. APMIS 119: 819-830.
6. Wekerle H (2008) Lessons from multiple sclerosis: models, concepts, observations. Ann Rheum Dis 67 Suppl 3: iii56-60.
7. Kroenke MA, Chensue SW, Segal BM (2010) EAE mediated by a non-IFN-gamma/non-IL-17 pathway. Eur J Immunol 40: 2340-2348.
8. Abromson-Leeman S, Bronson R, Luo Y, Berman M, Leeman R, et al. (2004) T-cell properties determine disease site, clinical presentation, and cellular pathology of experimental autoimmune encephalomyelitis. Am J Pathol 165: 1519-1533.
9. Muller DM, Pender MP, Greer JM (2005) Blood-brain barrier disruption and lesion localisation in experimental autoimmune encephalomyelitis with predominant cerebellar and brainstem involvement. J Neuroimmunol 160: 162-169.
10. Muller DM, Pender MP, Greer JM (2000) A neuropathological analysis of experimental autoimmune encephalomyelitis with predominant brain stem and cerebellar involvement and differences between active and passive induction. Acta Neuropathol 100: 174-182.
11. Kerlero de Rosbo N, Mendel I, Ben-Nun A (1995) Chronic relapsing experimental autoimmune encephalomyelitis with a delayed onset and an atypical clinical course, induced in PL/J mice by myelin oligodendrocyte glycoprotein (MOG)-derived peptide: preliminary analysis of MOG T cell epitopes. Eur J Immunol 25: 985-993.
12. Wensky AK, Furtado GC, Marcondes MC, Chen S, Manfra D, et al. (2005) IFN-gamma determines distinct clinical outcomes in autoimmune encephalomyelitis. J Immunol 174: 1416-1423.
13. Mannie M, Swanborg RH, Stepaniak JA (2009) Experimental autoimmune encephalomyelitis in the rat. Curr Protoc Immunol Chapter 15: Unit 15 12.
14. Adelmann M, Wood J, Benzel I, Fiori P, Lassmann H, et al. (1995) The N-terminal domain of the myelin oligodendrocyte glycoprotein (MOG) induces acute demyelinating experimental autoimmune encephalomyelitis in the Lewis rat. J Neuroimmunol 63: 17-27.
15. Mayer MC, Meinl E (2012) Glycoproteins as targets of autoantibodies in CNS inflammation: MOG and more. Ther Adv Neurol Disord 5: 147-159.
16. Menge T, Lalive PH, von Budingen HC, Genain CP (2011) Conformational epitopes of myelin oligodendrocyte glycoprotein are targets of potentially pathogenic antibody responses in multiple sclerosis. J Neuroinflammation 8: 161.
17. Hart BAt, Laman JD, Bauer J, Blezer E, van Kooyk Y, et al. (2004) Modelling of multiple sclerosis: lessons learned in a non-human primate. Lancet Neurol 3: 588-597.
18. von Budingen HC, Hauser SL, Ouallet JC, Tanuma N, Menge T, et al. (2004) Frontline: Epitope recognition on the myelin/oligodendrocyte glycoprotein differentially influences disease phenotype and antibody effector functions in autoimmune demyelination. Eur J Immunol 34: 2072-2083.
19. t Hart BA, Bauer J, Brok HP, Amor S (2005) Non-human primate models of experimental autoimmune encephalomyelitis: Variations on a theme. J Neuroimmunol 168: 1-12.
20. Brok HP, Bauer J, Jonker M, Blezer E, Amor S, et al. (2001) Non-human primate models of multiple sclerosis. Immunol Rev 183: 173-185.
21. Kerlero de Rosbo N, Brok HP, Bauer J, Kaye JF, t Hart BA, et al. (2000) Rhesus monkeys are highly susceptible to experimental autoimmune encephalomyelitis induced by myelin oligodendrocyte glycoprotein: characterisation of immunodominant T- and B-cell epitopes. J Neuroimmunol 110: 83-96.
22. Iglesias A, Bauer J, Litzenburger T, Schubart A, Linington C (2001) T- and B-cell responses to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis and multiple sclerosis. Glia 36: 220-234.
23. Bettelli E (2007) Building different mouse models for human MS. Ann N Y Acad Sci 1103: 11-18.
24. Marta CB, Oliver AR, Sweet RA, Pfeiffer SE, Ruddle NH (2005) Pathogenic myelin oligodendrocyte glycoprotein antibodies recognize glycosylated epitopes and perturb oligodendrocyte physiology. Proc Natl Acad Sci U S A 102: 13992-13997.
25. Oliver AR, Lyon GM, Ruddle NH (2003) Rat and human myelin oligodendrocyte glycoproteins induce experimental autoimmune encephalomyelitis by different mechanisms in C57BL/6 mice. J Immunol 171: 462-468.
26. Mannie MD, Paterson PY, U'Prichard DC, Flouret G (1990) The N- and C-terminal boundaries of myelin basic protein determinants required for encephalitogenic and proliferative responses of Lewis rat T cells. J Neuroimmunol 26: 201-211.
27. Massacesi L, Joshi N, Lee-Parritz D, Rombos A, Letvin NL, et al. (1992) Experimental allergic encephalomyelitis in cynomolgus monkeys. Quantitation of T cell responses in peripheral blood. J Clin Invest 90: 399-404.
28. Meeson AP, Piddlesden S, Morgan BP, Reynolds R (1994) The distribution of inflammatory demyelinated lesions in the central nervous system of rats with antibody-augmented demyelinating experimental allergic encephalomyelitis. Exp Neurol 129: 299-310.
29. Linington C, Engelhardt B, Kapocs G, Lassman H (1992) Induction of persistently demyelinated lesions in the rat following the repeated adoptive transfer of encephalitogenic T cells and demyelinating antibody. J Neuroimmunol 40: 219-224.
30. Fierz W, Heininger K, Schaefer B, Toyka KV, Linington C, et al. (1988) Synergism in the pathogenesis of EAE induced by an MBP-specific T-cell line and monoclonal antibodies to galactocerebroside or a myelin oligodendroglial glycoprotein. Ann N Y Acad Sci 540: 360-363.
31. Lassmann H, Brunner C, Bradl M, Linington C (1988) Experimental allergic encephalomyelitis: the balance between encephalitogenic T lymphocytes and demyelinating antibodies determines size and structure of demyelinated lesions. Acta Neuropathol 75: 566-576.
32. Linington C, Bradl M, Lassmann H, Brunner C, Vass K (1988) Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am J Pathol 130: 443-454.
33. Schluesener HJ, Sobel RA, Linington C, Weiner HL (1987) A monoclonal antibody against a myelin oligodendrocyte glycoprotein induces relapses and demyelination in central nervous system autoimmune disease. J Immunol 139: 4016-4021.
34. Hundgeburth LC, Wunsch M, Rovituso D, Recks MS, Addicks K, et al. (2013) The complement system contributes to the pathology of experimental autoimmune encephalomyelitis by triggering demyelination and modifying the antigen-specific T and B cell response. Clin Immunol 146: 155-164.
35. Szalai AJ, Hu X, Adams JE, Barnum SR (2007) Complement in experimental autoimmune encephalomyelitis revisited: C3 is required for development of maximal disease. Mol Immunol 44: 3132-3136.
36. Tran GT, Hodgkinson SJ, Carter N, Killingsworth M, Spicer ST, et al. (2002) Attenuation of experimental allergic encephalomyelitis in complement component 6-deficient rats is associated with reduced complement C9 deposition, P-selectin expression, and cellular infiltrate in spinal cords. J Immunol 168: 4293-4300.
37. Nataf S, Carroll SL, Wetsel RA, Szalai AJ, Barnum SR (2000) Attenuation of experimental autoimmune demyelination in complement-deficient mice. J Immunol 165: 5867-5873.
38. Mathey E, Breithaupt C, Schubart AS, Linington C (2004) Commentary: Sorting the wheat from the chaff: identifying demyelinating components of the myelin oligodendrocyte glycoprotein (MOG)-specific autoantibody repertoire. Eur J Immunol 34: 2065-2071.
39. Lee E, Chanamara S, Pleasure D, Soulika AM (2012) IFN-gamma signaling in the central nervous system controls the course of experimental autoimmune encephalomyelitis independently of the localization and composition of inflammatory foci. J Neuroinflammation 9: 7.
40. Lees JR, Golumbek PT, Sim J, Dorsey D, Russell JH (2008) Regional CNS responses to IFN-gamma determine lesion localization patterns during EAE pathogenesis. J Exp Med 205: 2633-2642.
41. Storch MK, Stefferl A, Brehm U, Weissert R, Wallstrom E, et al. (1998) Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol 8: 681-694.
42. Sakuma H, Kohyama K, Park IK, Miyakoshi A, Tanuma N, et al. (2004) Clinicopathological study of a myelin oligodendrocyte glycoprotein-induced demyelinating disease in LEW.1AV1 rats. Brain 127: 2201-2213.
43. Muhallab S, Dahlman I, Wallstrom E (2005) Disparate MHC class II haplotypes in myelin oligodendrocyte glycoprotein- and myelin basic protein-induced experimental autoimmune encephalomyelitis. J Neuroimmunol 161: 155-161.
44. t Hart BA, Elferink DG, Drijfhout JW, Storm G, van Blooijs L, et al. (1997) Liposome-mediated peptide loading of MHC-DR molecules in vivo. FEBS Lett 409: 91-95.
45. Meinl E, t Hart BA, Bontrop RE, Hoch RM, Iglesias A, et al. (1995) Activation of a myelin basic protein-specific human T cell clone by antigen-presenting cells from rhesus monkeys. Int Immunol 7: 1489-1495.
46. Geluk A, Elferink DG, Slierendregt BL, van Meijgaarden KE, de Vries RR, et al. (1993) Evolutionary conservation of major histocompatibility complex-DR/peptide/T cell interactions in primates. J Exp Med 177: 979-987.
47. Elferink BG, Geluk A, Otting N, Slierendregt BL, van Meijgaarden KE, et al. (1993) The biologic importance of conserved major histocompatibility complex class II motifs in primates. Hum Immunol 38: 201-205.
48. Bontrop RE, Elferink DG, Otting N, Jonker M, de Vries RR (1990) Major histocompatibility complex class II-restricted antigen presentation across a species barrier: conservation of restriction determinants in evolution. J Exp Med 172: 53-59.
49. Haanstra KG, Jagessar SA, Bauchet AL, Doussau M, Fovet CM, et al. (2013) Induction of experimental autoimmune encephalomyelitis with recombinant human myelin oligodendrocyte glycoprotein in Incomplete Freund's Adjuvant in three non-human primate species. J Neuroimmune Pharmacol.
50. Jagessar SA, Kap YS, Heijmans N, van Driel N, van Straalen L, et al. (2010) Induction of progressive demyelinating autoimmune encephalomyelitis in common marmoset monkeys using MOG34-56 peptide in incomplete freund adjuvant. J Neuropathol Exp Neurol 69: 372-385.
51. Frohman TC, Davis SL, Beh S, Greenberg BM, Remington G, et al. (2013) Uhthoff's phenomena in MS-clinical features and pathophysiology. Nat Rev Neurol 9: 535-540.